Decitabine or azacitidine plus venetoclax after transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests two cancer medicines—decitabine or azacitidine (also called “hypomethylating agents”) plus venetoclax—given after an allogeneic stem cell transplant to help prevent relapse in people with high-risk AML or MDS. If you have measurable remaining leukemia cells after transplant, this study may be especially relevant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had an allogeneic stem cell transplant (donor transplant) for AML or MDS.
- Your AML or MDS is considered high-risk, such as adverse lab genetics, needing more than two induction chemotherapy rounds for remission, TP53 mutation (for MDS), or measurable residual disease at the time of transplant.
- At the time of starting the study, your blood counts must meet limits: ANC ≥1.0, hemoglobin ≥80 g/L, and platelets ≥50 ×10^9/L.
- Your daily function must be OK: ECOG performance status 0–2 (able to do most self-care, possibly limited activity).
- You must not have certain problems: ongoing infection that isn’t controlled, serious organ problems, pregnancy or breastfeeding, or significant active graft-vs-host disease (GVHD).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving two drugs, decitabine and venetoclax, after a stem cell transplant can help keep your leukemia or MDS from coming back. It is for people whose disease is at high risk for relapse.
This trial tests adding two new drugs, decitabine and venetoclax, to a standard reduced-intensity stem cell transplant for people with certain types of leukemia or myelodysplastic syndrome. The goal is to see if this combination can improve outcomes.
This trial tests a combination of two drugs (venetoclax and azacitidine) followed by a stem cell transplant from a donor for patients with a specific type of acute myeloid leukemia (AML) that has low bone marrow cell count or has developed from a prior blood disorder. The goal is to control the disease and give you a chance at a cure through transplantation.
This trial tests whether giving Venetoclax and Azacitidine (VA) after your first remission helps keep you in remission before a stem cell transplant. It's for people with intermediate-risk AML who are planning to have a donor transplant.
This trial tests the combination of venetoclax (a targeted pill) and azacitidine (a chemotherapy-like drug) as consolidation therapy after initial treatment in adults with high-risk acute myeloid leukemia (AML) who have achieved remission and are planning a stem cell transplant. The goal is to see if this combination helps prevent relapse before transplant.
This trial tests a combination of two drugs (a demethylating agent and venetoclax) to help prevent high-risk T-cell lymphoma or leukemia from coming back after a stem cell transplant. It is for patients who have certain risk factors for relapse.
Hear when a new Myeloid Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.